Loading...
Generating destination analysis
Catalyst Play
Featured in “Three Biotech Stocks to Buy Before ASCO's Biggest Data Drop”
ASCO May 29
Recursion Pharmaceuticals uses AI to discover drugs at a fraction of traditional cost and time. Multiple clinical programs are reporting data at ASCO 2026. A single hit validates the entire AI drug discovery model — and Recursion has more shots on goal than anyone else in the space.
The catalyst: The American Society of Clinical Oncology (ASCO) annual meeting — May 29 to June 2 in Chicago — is the most important event in cancer drug development. Over 40,000 oncology professionals gather for late-stage clinical trial data presentations that routinely move biotech stocks 30–50% in a single session. These three companies have the most anticipated data readouts at ASCO 2026, and the results will determine their trajectory for years.
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Unlock Full RXRX Analysis
UpgradeKey Numbers
Market Cap
$4B
P/E
N/A
Revenue Growth
+55.0%
Gross Margin
N/A
ROE
N/A
About Recursion Pharmaceuticals
Listed on the NASDAQ, Recursion Pharmaceuticals operates as a small-cap player in the biotech sector, offering investors focused access to biotech and genomics growth drivers. AI-driven drug discovery platform using machine learning to decode biology at scale. With a $4B market capitalization and no current profitability, the business is characterized by exceptional revenue growth, reporting +55% revenue change year-over-year.
Expert Coverage
Loading coverage...
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-03-22
More in Biotech & Genomics
ARKG
ARK Genomic Revolution ETF
89
True North
Mixed
ETF focused on companies advancing genomics, gene editing, and therapeutics.
CBOE
MCap $2BDXCM
DexCom Inc.
85
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55ALNY
Alnylam Pharmaceuticals
85
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%LLY
Eli Lilly and Company
85
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65